311 related articles for article (PubMed ID: 24002871)
1. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma.
Wang L; Zhang X; Jia LT; Hu SJ; Zhao J; Yang JD; Wen WH; Wang Z; Wang T; Zhao J; Wang RA; Meng YL; Nie YZ; Dou KF; Chen SY; Yao LB; Fan DM; Zhang R; Yang AG
Hepatology; 2014 May; 59(5):1850-63. PubMed ID: 24002871
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma.
Zhang X; Zhang X; Wang T; Wang L; Tan Z; Wei W; Yan B; Zhao J; Wu K; Yang A; Zhang R; Jia L
Cancer Lett; 2018 Jul; 426():98-108. PubMed ID: 29653269
[TBL] [Abstract][Full Text] [Related]
5. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma.
Huang D; Wang X; Zhuang C; Shi W; Liu M; Tu Q; Zhang D; Hu L
Oncol Rep; 2016 Feb; 35(2):1083-90. PubMed ID: 26718325
[TBL] [Abstract][Full Text] [Related]
8. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
[TBL] [Abstract][Full Text] [Related]
9. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
Xia H; Ooi LL; Hui KM
PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling.
Zhao J; Li H; Zhao S; Wang E; Zhu J; Feng D; Zhu Y; Dou W; Fan Q; Hu J; Jia L; Liu L
Mol Cancer; 2021 Mar; 20(1):46. PubMed ID: 33658044
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
[TBL] [Abstract][Full Text] [Related]
12. A double-negative feedback loop between EZH2 and miR-26a regulates tumor cell growth in hepatocellular carcinoma.
Zhuang C; Wang P; Huang D; Xu L; Wang X; Wang L; Hu L
Int J Oncol; 2016 Mar; 48(3):1195-204. PubMed ID: 26781064
[TBL] [Abstract][Full Text] [Related]
13. C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells.
Li SG; Shi QW; Yuan LY; Qin LP; Wang Y; Miao YQ; Chen Z; Ling CQ; Qin WX
J Exp Clin Cancer Res; 2018 Mar; 37(1):51. PubMed ID: 29523159
[TBL] [Abstract][Full Text] [Related]
14. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
15. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q
Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2.
Wang B; Hsu SH; Wang X; Kutay H; Bid HK; Yu J; Ganju RK; Jacob ST; Yuneva M; Ghoshal K
Hepatology; 2014 Feb; 59(2):555-66. PubMed ID: 24038073
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans.
Yang F; Zhang L; Huo XS; Yuan JH; Xu D; Yuan SX; Zhu N; Zhou WP; Yang GS; Wang YZ; Shang JL; Gao CF; Zhang FR; Wang F; Sun SH
Hepatology; 2011 Nov; 54(5):1679-89. PubMed ID: 21769904
[TBL] [Abstract][Full Text] [Related]
19. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
20. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
